Management of intractable spasticity of supraspinal origin by chronic cervical intrathecal infusion of baclofen.
Today it is accepted that chronic infusion of baclofen produces significant relaxation and drastic reduction of spasms, amelioration of cramping pain and improvement of sphincter functions in spasticity of spinal cord origin. Based on these results our group had the opportunity of treating 11 cases with refractory spasticity and dystonic symptoms due to central damage caused by head injury in 8 cases and to cerebral palsy in 3 using cervical intrathecal infusion of baclofen. During the trial period with percutaneous intrathecal infusion of a daily bolus of 12.5-75 micrograms of baclofen through a reservoir, improvement of mentation and speech conditions, marked improvement of dystonic and abnormal movements of the upper limbs and trunk and a notable reduction of hypertonia were observed in all cases, which led to a better performance of motor activities in skilled acts and transfer. With these preliminary results in mind, in all cases the previous cervical subarachnoid catheter was attached to a programmable pump that infused a daily total dose varying from 100 to 190 micrograms of baclofen in a continuous or multistep complex mode. After a mean follow-up of 21 months previous results were long-lasting. Neither overdose side effects nor malfunction of the system were observed.
Conçalves
J
J
Department of Neurosurgery, University of Salamanca, Spain.
García-March
G
G
Sánchez-Ledesma
M J
MJ
Onzaín
I
I
Broseta
J
J
D000293:Adolescent; D000328:Adult; D001418:Baclofen / Q000627:therapeutic use*; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D015918:Infusion Pumps, Implantable; D008297:Male; D008875:Middle Aged; D009128:Muscle Spasticity / Q000188:drug therapy*; D009333:Neck; D013116:Spinal Cord / Q000187:drug effects; D016896:Treatment Outcome
D001418:Baclofen